Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multi-center, Phase I Clinical Study to Evaluate the Safety and Tolerability of Multi-antigen Autologous Immune Cell Injection (MASCT-I) in Patients With Advanced Solid Tumor, and to Preliminarily Evaluate the Anti-tumor Efficacy of MASCT-I Alone, in Combination With Chemical Drugs, and in Combination With PD1 Antibody

Next Previous
Trial Profile

Multi-center, Phase I Clinical Study to Evaluate the Safety and Tolerability of Multi-antigen Autologous Immune Cell Injection (MASCT-I) in Patients With Advanced Solid Tumor, and to Preliminarily Evaluate the Anti-tumor Efficacy of MASCT-I Alone, in Combination With Chemical Drugs, and in Combination With PD1 Antibody

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Camrelizumab (Primary) ; MASCT I (Primary) ; Antineoplastics; Carboplatin; Cisplatin; Doxorubicin; Gemcitabine; Ifosfamide; Platinum complexes
  • Indications Bladder cancer; Carcinoma; Cholangiocarcinoma; Osteosarcoma; Soft tissue sarcoma; Solid tumours; Ureteral neoplasms; Urethral cancer; Urogenital cancer
  • Focus Adverse reactions
  • Sponsors HengRui YuanZheng Bio-Technology; SYZ Cell Therapy

Most Recent Events

  • 03 Jun 2025 Planned number of patients changed from 193 to 105.
  • 03 Jun 2025 Planned End Date changed from 1 Jul 2023 to 1 Jul 2026.
  • 04 Jun 2024 Updated results on multiple antigens stimulating cellular therapy (MASCT-I) in metastatic urothelial carcinoma presented at the 60th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top